Lead Product(s) : Licaminlimab
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : $59.0 million
Deal Type : Financing
Oculis Announces Completion Of $59 Million Registered Direct Offering and Nasdaq Listing
Details : Oculis intends to use net proceeds to advance its clinical development pipeline, OCS-02 (licaminlimab), a novel TNF alpha antibody eye drop currently being investigated in phase 2 for dry eye disease.
Product Name : OCS-02
Product Type : Antibody
Upfront Cash : Undisclosed
November 04, 2024
Lead Product(s) : Licaminlimab
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : $59.0 million
Deal Type : Financing
Lead Product(s) : Licaminlimab
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Oculis' Licaminlimab Shows Positive Results for Dry Eye with a Precision Medicine Strategy
Details : Oculis' investigational product OCS-02 (licaminlimab) is an innovative anti-TNFα biologic eye drop. It is currently undergoing Phase II clinical trial evaluation for treating Dry Eye Disease.
Product Name : OCS-02
Product Type : Antibody
Upfront Cash : Inapplicable
October 06, 2024
Lead Product(s) : Licaminlimab
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Licaminlimab
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : BBA//Fjeldco
Deal Size : $59.0 million
Deal Type : Financing
Oculis Announces Closing Of Registered Direct Offering and Nasdaq Iceland Listing
Details : Oculis intends to use net proceeds to advance its clinical pipeline, OCS-02 (licaminlimab), a novel TNF alpha antibody eye drop being investigated in phase 2 for dry eye disease.
Product Name : OCS-02
Product Type : Antibody
Upfront Cash : Undisclosed
April 22, 2024
Lead Product(s) : Licaminlimab
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : BBA//Fjeldco
Deal Size : $59.0 million
Deal Type : Financing
Lead Product(s) : GT005
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
GT005 (PPY988): Development Program in Geographic Atrophy
Details : GT005 (PPY988) is an investigational ocular gene therapy, which is investigated for the treatment of Geographic Atrophy (GA) secondary to dry-Age-related Macular Degeneration (dry-AMD).
Product Name : GT005
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
November 09, 2023
Lead Product(s) : GT005
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Licaminlimab
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Oculis' investigational product OCS-02 (licaminlimab) is an innovative anti-TNFα biologic eye drop. It is currently undergoing Phase II clinical trial evaluation for treating Dry Eye Disease.
Product Name : OCS-02
Product Type : Antibody
Upfront Cash : Inapplicable
July 12, 2023
Lead Product(s) : Licaminlimab
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pamapimod,Pioglitazone
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Kinarus Receives USPTO Notice of Allowance for Lead Therapeutic Candidate KIN001
Details : KIN001 is combination of two APIs: pamapimod and pioglitazone. Kinarus has found that combining pamapimod with pioglitazone, leads to synergistic efficacy and increased duration of action in preclinical models of wet AMD, IPF and fibrotic and inflammator...
Product Name : KIN001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 22, 2022
Lead Product(s) : Pamapimod,Pioglitazone
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Licaminlimab
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Licaminlimab (OCS-02) is an anti-TNFα antibody product candidate to be administered topically. Its dual MoA, anti-inflammation and anti-necrosis, is clinically proven with other anti-TNFα antibodies already approved as systemic treatment for ocular dis...
Product Name : OCS-02
Product Type : Antibody
Upfront Cash : Inapplicable
November 22, 2022
Lead Product(s) : Licaminlimab
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Licaminlimab
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Primary and secondary efficacy endpoints were successfully met and showed superiority of OCS-02 (licaminlimab) over vehicle for the relief of ocular discomfort in patients with severe DED.
Product Name : OCS-02
Product Type : Antibody
Upfront Cash : Inapplicable
August 23, 2022
Lead Product(s) : Licaminlimab
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dipraglurant
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Addex Provides Update on Dipraglurant Blepharospasm Phase 2 Feasibility Clinical Study
Details : ADX48621 (dipraglurant), is a metabotropic glutamate receptor subtype 5 negative allosteric modulator, or mGlu5 NAM. It’s lead indication is levodopa induced dyskinesia associated with Parkinson’s disease, or PD-LID.
Product Name : ADX48621
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 27, 2022
Lead Product(s) : Dipraglurant
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dipraglurant
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Addex Therapeutics Initiates Phase 2 Clinical Study with Dipraglurant in Blepharospasm
Details : The double-blind, randomized Phase 2a feasibility study will enroll 15 patients with blepharospasm. It is designed to assess the safety and tolerability of dipraglurant as well as explore its effects on the severity and frequency of blepharospasm signs a...
Product Name : ADX48621
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 29, 2021
Lead Product(s) : Dipraglurant
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable